Phase 2 Oesophageal Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have given written consent before any study procedures begin.
• People aged between 18 and 75 years old (inclusive), of any gender.
• People who have been confirmed through a tissue sample (biopsy) to have a specific type of esophageal (food pipe) cancer called squamous cell carcinoma, at a locally advanced but operable stage, meeting specific staging criteria as defined by the trial.
• People whose neck lymph nodes show no suspicious signs on ultrasound or CT scan, and whose scans show no sign of cancer spreading to other parts of the body.
• People whose cancer is expected to be fully removable by surgery with no cancer left behind (known as R0 resection).
• People who have at least one measurable tumor visible on imaging.
• People with a good general health and activity level, rated 0 or 1 on a standard medical scale (ECOG), meaning they are fully active or have only minor limitations in physical activity.
• People expected to live for at least 3 months.
• People with normal thyroid hormone levels, or whose thyroid-stimulating hormone is slightly outside the normal range but whose other thyroid hormones are normal.
• People whose blood, liver, kidney, and clotting test results meet the specific levels required by the trial, without having received blood transfusions or certain blood-boosting treatments in the 14 days beforehand.
• People whose heart is pumping at a sufficient level, with a heart function score (left ventricular ejection fraction) of 50% or above.
• Women of childbearing age who have a negative pregnancy test at the screening stage.
• People of reproductive capacity who are willing to use reliable contraception from the time of signing consent until 90 days after the last dose of the study drug.
• People who are willing and able to follow the trial schedule, including all visits, treatments, and tests.

Who may not be able to join:

• People who have had another type of cancer within the past 5 years, unless it was a very localised or non-invasive cancer (such as certain skin cancers, early bladder cancer, or early-stage cervical or breast changes) that was treatable with local therapy only.
• People who have previously been treated with certain immune checkpoint drugs (such as PD-1 or PD-L1 inhibitors), other immune-targeting drugs (such as CTLA-4 or OX-40 treatments), or anti-blood vessel growth drugs (such as bevacizumab or endostar).
• People who have received certain immune-boosting therapies (such as interleukins, interferons, or thymopentin), or certain traditional herbal medicines with anti-cancer indications, within 2 weeks before the first study dose.
• People who have an active autoimmune disease (where the immune system attacks the body) that currently requires systemic treatment such as immune-suppressing drugs or steroids — though hormone replacement therapies for conditions like an underactive thyroid or adrenal insufficiency are not considered disqualifying.
• People who have cancer that has spread to the brainstem, the lining of the brain, or the spinal cord, or who have signs of pressure or compression in those areas.
• People who have significant fluid build-up around the lungs, heart, or abdomen that requires ongoing medication or repeated draining.
• People who have had a serious bowel blockage, a hole in the gut, an abscess in the abdomen, or an abnormal passage (fistula) in the digestive tract within 6 months before the first dose.
• People who have active inflammatory bowel conditions such as Crohn's disease, ulcerative colitis, radiation-related gut damage, bleeding bowel disease, or ongoing diarrhoea.
• People whose scans show the tumour is wrapped around major blood vessels, or show significant tissue death or cavities in the tumour, where the trial doctors consider there to be a bleeding risk.
• People who have moderate or severe scarring or inflammation of the lung tissue (interstitial lung disease, Grade 2 or higher).
• People with serious heart or blood vessel conditions, including: uncontrolled high blood pressure or high blood pressure in the lungs; unstable chest pain, a heart attack, heart bypass surgery, or a stent fitted within the past 6 months; significant heart failure; a heart pumping function below 50%; certain serious irregular heart rhythms; or a stroke or mini-stroke (TIA) within the past 4 weeks.
• People who have had a serious infection (such as blood poisoning or severe pneumonia) within 4 weeks before the first dose, or who have been on systemic antibiotics or antimicrobial treatment for an active infection within 2 weeks before the first dose (antiviral treatment for hepatitis B or C is not considered disqualifying).
• People with known active tuberculosis (TB) or active syphilis — suspected TB cases must be medically assessed and ruled out before joining.
• People who test positive for HIV antibodies, or who have active hepatitis B or hepatitis C infection (confirm with trial site for full details on this criterion).

Important: Always verify eligibility with the trial site directly before applying.